Saturday, December 23, 2006

Epirubicin-Based Regimen Treats Inflammatory Breast Cancer

Epirubicin-based induction and maintenance chemotherapy leads to relatively high long-term survival rates in women with unilateral inflammatory breast cancer, French researchers report in the December 1st issue of Cancer. Dr. Corinne Veyret of Centre Henri Becquerel, Rouen and colleagues evaluated the long-term efficacy and side effects of this treatment in 120 patients with nonmetastatic disease. The patients were randomized to high-dose fluorouracil, epirubicin and cyclophosphamide (FEC) with or without lenograstim or placebo. They also underwent surgery, radiation therapy or both. Maintenance therapy was with FEC at lower doses and no hormone therapy was employed. No differences in outcome were seen between the lenograstim and placebo groups and overall; 76 patients (63.3%) developed recurrent disease. --Click the title of this post to read the full article from its source--

Labels: , ,

Treatment-Induced Amenorrhea May Prevent Breast Cancer Relapse: Presented at SABCS

Treatment-induced amenorrhea during chemotherapy for breast cancer is associated with a significant 44% reduction in relapse risk in women under 40 years of age, a prospective, randomized study shows.Michael Gnant, MD, professor of surgery, Medical University of Vienna, Austria, presented the results on behalf of the Austrian Breast & Colorectal Cancer Study Group here on December 15th at the 29th Annual San Antonio Breast Cancer Symposium (SABCS).The study involved 1,099 premenopausal women with estrogen- or progestin-receptor-positive, Stage I or II breast cancer. Following surgery, the women were randomized to 1 of 2 treatment regimens: 1) ovarian suppression with 3.6 mg of goserelin (Zoladex) every 28 days for 3 years and 20 mg/day of tamoxifen for 5 years; 2) 6 cycles of chemotherapy consisting of cyclophosphamide (Cytoxan) 600 mg/m2 combined with methotrexate 40 mg/m2, and fluorouracil (Adrucil) 600 mg/m2 intravenously on days 1 and 8. --Click the title of this post to read the full article from its source--

Labels: , , , , , ,

/* WebRing Code */